N'-(11H-Indolo[3,2-c]quinolin-6-yl)-N,N-dimethylethane-1,2-diamine(IQDMA)屬於indoloquinoline的衍生物之ㄧ,對人類許多腫瘤細胞具有毒殺作用。在本實驗中,我們將HL-60人類血癌細胞加入IQDMA,經24小時後分析其結果,發現IQDMA會使細胞週期停滯在S phase,而且會導致細胞產生apoptosis。因此首先我們分析有關S phase的調控因子,發現IQDMA會降低Cdk1, Cdk2 和 cyclin A的表現量,但對cyclin B1, cyclin D3和p21則無影響,此結果與S phase arrest的現象有關;另外我們也發現,IQDMA會促使Bax量增加,使Bcl-2:Bax的比例改變,進而活化caspase-3和-9,導致下游的PARP的斷裂,最後使細胞走向apoptosis。而我們也發現IQDMA會增加p-ERK的表現量,但JNK和p38則不受影響,我們也進一步求證p-ERK的增加與細胞apoptosis關係,發現並無直接的影響,綜合以上結果,我們得知IQDMA會導致HL-60人類血癌細胞,產生細胞週期停滯及細胞凋亡的現象。
N’-(11H-indolo[3,2-c]quinolin-6-yl)-N,N-dimethylethane-1,2-diamine(IQDMA), an indoloquinoline compound, was a novel antineoplastic agent with a broad spectrum of antitumor activity against many human cancer cells. Cell cycle analysis showed S phase arrest and induction of apoptosis in HL-60 cells following 24 h exposure to IQDMA. Analysis of the cell cycle regulatory proteins demonstrated that IQDMA did not change the steady-state levels of cyclin B1, cyclin D3, and p21, but decreased the protein levels of Cdk1, Cdk2 and cyclin A. IQDMA also caused a marked increase in apoptosis, which was accompanied by increased level of Bax, activated caspase-3, -8, and -9, and cleaved PARP.IQDMA increased the levels of p-ERK but did not change in JNK and p38. However, ERK inhibitor showed no altered the viability of IQDMA-treated HL-60 cells, suggesting that the activation of ERK is not associated with IQDMA-induced cell death. These molecular alterations provide an insight into IQDMA-caused growth inhibition S phase arrest and apoptotic death of HL-60 cells.